William Blair downgraded Sarepta Therapeutics (NASDAQ:SRPT) to market perform from outperform saying the company has limited near-term upside as a result of a decline in its peak revenue opportunity.

The HHS said center directors deserve to be supported by managers aligned with aggressive goals “to expeditiously advance therapeutics for rare diseases using the gold standard of science.” ...